Here are the 10-K annual reports from Vyome Holdings, Inc. (HIND) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow HIND and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HIND filings page.
Vyome Holdings, Inc. (formerly ReShape Lifesciences) is a clinical-stage specialty pharmaceutical company focused on immune‑inflammatory and rare diseases, built around a US‑India R&D corridor. Following an August 2025 merger with Vyome Therapeutics, it now operates biotechnology and pharmaceutical product segments.
The lead candidate, VT‑1953, is a topical gel based on besifloxacin, being developed to treat symptoms of malignant fungating wounds in advanced cancer. Early studies in acne showed low systemic exposure and favorable safety. An investigator‑initiated phase 2 study in malignant fungating wounds reported statistically significant reductions in malodor, pain, and quality‑of‑life impact versus vehicle over 14 days.
Additional programs include VT‑1908, an ophthalmic immune modulator for anterior uveitis at pre‑IND stage, and VB‑1953 for moderate to severe acne, which has completed phase 2 and is described as phase 3‑ready. Vyome also licenses reformulated antifungal products in India through Sun Pharma. As of March 17, 2026, 7,018,528 common shares were outstanding, and non‑affiliate market value at June 30, 2025 was $6.4 million.